BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma
ConditionHodgkin Lymphoma (Category)
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorXiuhua Sun
About this trial
The goal of this clinical trial is to explore the real-world Chinese relapsed/refractory patients to evaluate the efficacy and safety of BV monotherapy or combination therapy in CHL patients. The main questions it aims to answer are:
To evaluate the efficacy and toxicity of BV-containing regimen in relapsed/refractory CHL patients in China, and to provide reference for the rational and safe use of BV in clinical practice.
Eligibility criteria
Qualifiers
Histologically, classical hodgkin lymphoma（cHL） was diagnosed and relapsed or refractory.
Patients were treated with BV-containing regimen at least once
Presence of tumor (measurable or nonmeasurable).
Signature of the form consent for participation in the study.
Disqualifiers
<18 years
Trial design
Treatments tested in this trial
- Brentuximab Vedotin (Bv)
- Sintilimab
- Tislelizumab
- Bendamustine
Treatment groups
100 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Xiuhua Sun
Lead sponsor
Dalian Medical University
Sponsor institution
Source ClinicalTrials.gov